Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), an ophthalmic pharmaceutical company based in California, and the Choroideremia Research Foundation (CRF), a non-for-profit patient organisation focused on the… Read More »Kiora Pharmaceuticals Inc. have announced a partnership with the Choroideremia Research Foundation for novel treatments.
Results of a biosimilar agent (SB15) of aflibercept (Eylea) have reported comparable outcomes between the generic version and the reference drug (aflibercept) for naïve neovascular… Read More »A biosimilar of aflibercept (“SB15”) indicates comparability to the reference drug for neovascular AMD.
Research conducted at Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, has reported three approaches to test novel strategies to treat a range of… Read More »Research for testing end-stage therapies for retinal degenerations for non-human primate (NHP) models.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 10th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »August 10th, 2023 “EURETINA-Brief”© Issue No. 276
According to the ASRS Research and Safety in Therapeutics (ReST) Committee, a small number of cases of occlusive retinal vasculitis has been observed between 7… Read More »The American Society of Retina Specialists (ASRS) has reported at least six cases of occlusive retinal vasculitis following injection of Syfovre (pegcetacoplan).
Researchers at Schulich School of Medicine and Dentistry, Western University, Ontario, Canada, reported a meta-analysis among AMD patients finding reduced incomes and reduced employment following… Read More »Research on AMD patients’ productivity and participation in the labour market.
Researchers at the University of Alabama, Birmingham, USA and Queensland University of Technology, Brisbane, Australia, have reported a study on the most highly cited articles… Read More »A first global analysis on ophthalmic journals and authors measuring the h-index – metrics for measuring scientific performance.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 21st, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »July 21st, 2023 “EURETINA-Brief”© Issue No. 275
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics… Read More »FDA has declined approval of Regeneron’s higher dose (8mg) of Eylea, understood to be a review of inspection findings at a third-party filler.
Researchers at the Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Italy and the Centre of Public Health, Queen’s University… Read More »Anti-VEGF treatments for diabetic macula oedema (DMO) reports Cochrane review meta-analysis.
